Boltz PBC spun out of MIT with a $28 million seed round to commercialize a suite of open, AI‑driven drug discovery models developed at CSAIL. Led by co‑founders from Regina Barzilay’s group, the company launched as a public‑benefit corporation aiming to make high‑accuracy structure prediction and molecule design tools broadly available to academic and industry researchers. Investors including Amplify, a16z and Zetta backed the seed. Boltz unveiled Boltz Lab and early agents for small‑molecule and protein design, positioning its platform as infrastructure for many scientists rather than a single‑asset therapeutics company—an atypical model intended to accelerate molecule generation at scale.